You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)CS1001聯合含鉑化療一線治療晚期非小細胞肺癌安全性良好
格隆匯 05-26 22:37

格隆匯5月26日丨基石藥業(02616.HK)公佈將在美國臨牀腫瘤學會(ASCO)2020年年會上,以摘要的形式公佈其PD-L1單克隆抗體CS1001的CS1001-101研究最新數據。

更新的數據顯示CS1001聯合含鉑化療一線治療晚期非小細胞肺癌(NSCLC),在非鱗NSCLC和鱗狀NSCLC兩個隊列中,客觀緩解率(ORR)分別為47.6%和75%;安全性良好,未發生CS1001相關的導致患者退出研究的不良事件。

基石藥業首席醫學官楊建新博士表示:很高興的看到CS1001聯合含鉑化療顯示了優異的抗腫瘤活性和良好的安全性數據,這一最新數據再次支持CS1001聯合化療在晚期一線NSCLC的探索。基石藥業目前已經完成了CS1001聯合含鉑化療一線治療晚期NSCLC的三期臨牀研究的患者招募,預計會在接下來幾個月時間公佈主要研究結果。值得一提的是這項研究是中國首個同時涵蓋鱗狀NSCLC和非鱗NSCLC兩種亞型的三期一線臨牀研究。隨着Ⅰb期ORR和無進展生存期等數據的完善,公司有信心也非常期待Ⅲ期研究的結果。

據悉,CS1001-101研究是一項針對晚期實體瘤或淋巴瘤患者開展的旨在評估CS1001的安全性、耐受性、藥代動力學特徵和抗腫瘤療效的Ⅰ期研究。在本次ASCO年會上基石藥業將發表CS1001-101研究中晚期NSCLCⅠb期隊列的療效驗證數據。該隊列研究的目的是評估CS1001聯合含鉑化療一線治療NSCLC的療效和安全性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account